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Binge/crash cycles of methamphetamine (MA) use are frequently reported by individuals
suffering from MA use disorders. A MA binge is self-reported as multiple daily doses
that commonly accumulate to 800mg/day (∼10mg/kg/day for a 170 pound human).
A genetic animal model with a similar vulnerability to binge-level MA intake is missing.
We used selectively bred MA high drinking (MAHDR) and low drinking (MALDR) mouse
lines to determine whether several procedural variations would result in binge-level MA
intake. Data were also collected in two progenitor populations of the MA drinking lines,
the DBA/2J (D2) strain and the F2 cross of the D2 and C57BL/6J strains. The impact
of 3 factors was examined: (1) concentration of MA in the two-bottle choice procedure
used for selective breeding; (2) ratio of bottles containing MA vs. water, and (3) length
of the withdrawal (or abstinence) period between MA drinking sessions. When MA
concentration was progressively increased every 4 days in 20mg/l amounts from 20
to 140mg/l, maximum intake in MALDR mice was 1.1mg/kg, whereas MAHDR mice
consumed as much as 14.6mg/kg. When these concentrations were tested in a multiple
bottle choice procedure, the highest ratio of MA to water bottles (3:1) was associated
with escalated MA intake of up to 29.1mg/kg in MAHDR mice and 12.0mg/kg in F2
mice; MALDR mice did not show a ratio-dependent escalation in MA intake. Finally,
MAHDR and D2 mice were offered 3 bottles of MA vs. water at increasing concentrations
from 20 to 80mg/l, and tested under an intermittent 6-h withdrawal period, which was
lengthened to 30 h (D2 mice) or to 30 or 78 h (MAHDR). D2 and MAHDR mice initially
consumed similar amounts of 14–16mg/kg MA, but D2 mice reduced their MA intake
3-fold after introduction of 30-h abstinence periods, whereas MAHDRmice retained their
high level of intake regardless of withdrawal period. MAHDR mice provide a genetic
model of binge-level MA intake appropriate for the study of associated MA-induced
neurobiological changes and pharmaceutical treatments.
Keywords: voluntary consumption, self-administration, selected line, genetic, withdrawal, abstinence, MALDR,
MAHDR
INTRODUCTION
The path to problematic methamphetamine (MA) use leading to a diagnosable disease state is
characterized in some individuals by gradual, persistent increases in use, often waxing and waning
in so-called binge/crash cycles. Binge/crash cycles are well characterized for psychostimulants,
and are thought to contribute to escalation of drug use, which is a hallmark of drug dependence
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(Roberts et al., 2013). A subgroup of MA users that were
categorized as binge users, based on self-reported periods of high
MA use until taking a break to sleep, also reported higher overall
MA intake and more frequent use (Simon et al., 2002; Cheng
et al., 2010). The likelihood of binge use is somewhat higher
for younger MA users, though length of MA use seems not to
have a significant effect on probability of binge use (Cheng et al.,
2010). In other individuals, a more continuous pattern of use
is typical, with MA use in the morning and at regular intervals
throughout the day, rarely skipping days. This pattern is different
from that of most cocaine users, which is more binge-like (Huber
et al., 1997; Rawson et al., 2000; Simon et al., 2002). Amounts of
MA consumed in a day on average for both types of users were
between 0.3 and 0.8 g, though they could be as high as 1–4 grams
in a binge cycle which lasts 1–3 days (Cho et al., 2001; Simon et al.,
2002).
There is some evidence that genetic factors influence risk
for a MA use disorder (e.g., Hong et al., 2003; Kinoshita
et al., 2008; Uhl et al., 2008). However, lower rates of MA
sampling, compared to some other drugs like nicotine and
alcohol, impact the validity of genome-wide association studies
in which a non-abusing control population is compared to a
MA-dependent population. This is because many individuals
in the control group are unlikely to have been exposed to
MA, and thus, they may be mischaracterized. This is less of a
problem for a drug like alcohol, which is widely sampled and
readily available. Thus, other approaches to genetic investigation
are important, including the use of genetic animal models
in which drug history, environmental history, and genetic
composition can be better controlled. Furthermore, despite
extensive investigation, there are currently no food and drug
administration-approved medications for the treatment of MA
use disorder, and the identification of genetic risk and protective
factors could lead to novel therapeutic targets (e.g., Harkness
et al., 2015).
The gold standard for studying motivation to seek and self-
administer MA in animals has been operant intravenous (IV)
self-administration in rodents (Sanchis-Segura and Spanagel,
2006). However, studies exploring genetic risk for voluntary
MA intake have been scant (de Wit and Phillips, 2012), in
part, because rat or mouse models using IV procedures are
not amenable to large scale genetic studies, which require
large group sizes (e.g., ∼120 animals per generation in a
selective breeding project). MA administered through the
oral route is readily absorbed in the digestive tract and,
although details of the MA experience are different, is well
documented to result in problematic levels of use similar to
when administered through IV or nasal routes (Cruickshank
and Dyer, 2009). Thus, we utilized a two-bottle choice MA
drinking procedure to develop our mouse model of high
and low genetic risk for MA use. Bidirectional short-term
selective breeding methods (Belknap et al., 1997) were used
to produce multiple replicate sets of MA drinking (MADR)
selected lines in which one member of each set was MA
high drinking (MAHDR) and the other was MA low drinking
(MALDR). These mice have been used to identify genetic risk
factors and genetically-correlated traits that are associated with
protection from excessive MA intake (Phillips and Shabani,
2015).
The MAHDR lines of mice consume roughly 6mg/kg/18 h
on average from the 40mg/l MA solution, whereas the MALDR
lines consume roughly 0.4mg/kg/18 h. In a 77 kg (or 170 lb)
human, 500mg/day would be in the middle of the common
range of use, which is 6.5mg/kg. Thus, in this relatively short
duration MA intake model, relevant levels of intake are attained.
Considerable data indicate that taste factors do not account for
differences in MA intake between the MADR lines (Wheeler
et al., 2009; Shabani et al., 2011), including data indicating that
the lines consume comparable MA on the first day of access
(Shabani et al., 2012a; Eastwood et al., 2014). In addition, only
the MAHDR line establishes operant intracranial and oral self-
administration of MA (Shabani et al., 2012a). However, for
the purpose of characterizing neurochemical consequences and
identifying therapeutic interventions, a longer term model with
higher levels of intake is desirable.
In the current research, certain characteristics of the MA
drinking procedure were manipulated to determine the impact
on MA intake. The purpose was to identify a procedure(s)
that would result in binge-like levels of consumption. Three
factors were manipulated. First, the concentration of MA in
the two-bottle choice procedure was progressively increased up
to a concentration of 140mg/l. Next, this manipulation was
retained and the ratio of the number of bottles containing
MA vs. water was varied across groups. The bottle ratio
manipulation was based on data for ethanol drinking in which
the amount of ethanol consumed by both C57BL/6J (B6; a
high ethanol-consuming mouse strain) and 129X1/SvJ (a low
to moderate ethanol-consuming strain) was positively related
to the number of ethanol-containing bottles available (Tordoff
and Bachmanov, 2003). This design has not been tried for MA.
Finally, because human studies suggest that intermittency and
cycles of abstinence have integral roles in the development of a
drug use disorder, the length of the withdrawal period between
MA access periods in our intermittent access procedure was
manipulated. In general, in prolonged drinking procedures we
predicted binge-like patterns of MA intake to emerge in the
MAHDR mice. We specifically predicted that MAHDR mice
would consume higher amounts of MA as MA concentration
increased, in part, because lower volumes could be consumed
to obtain a higher dose, but also because MAHDR mice exhibit
low sensitivity to aversive effects of MA and high sensitivity to
MA-conditioned reward and MA reinforcement (Wheeler et al.,
2009; Shabani et al., 2011, 2012a,b; Harkness et al., 2015). We
also predicted that more MA would be consumed by MAHDR
mice when the ratio of MA to water bottles was higher, based
on Tordoff and Bachmanov (2003). There are no free-choice
MA intake studies that have examined the impact of withdrawal
period. However, based on alcohol intake studies with DBA/2J
(D2) and B6 mice (Cunningham et al., 2013; Dreumont and
Cunningham, 2014), we predicted that short acute withdrawal
periods within a day between MA access periods would sustain
or even enhance MA intake, whereas longer withdrawal periods
of days between MA access periods would attenuate MA
intake.
Frontiers in Neuroscience | www.frontiersin.org 2 November 2016 | Volume 10 | Article 493
Shabani et al. Binge-Level Methamphetamine Use
MATERIALS AND METHODS
Animals
Methamphetamine Drinking (MADR) Lines
TheMADR lines were generated from a reciprocal F2 cross of the
B6 and D2 inbred strains, based on their voluntary MA intake
in a two-bottle choice procedure. In this procedure, animals are
given continuous access to a water bottle and access to 20mg/l
MA for 18 h/day for 4 days and then to 40mg/l MA for another 4
days (Wheeler et al., 2009; Shabani et al., 2011). Based on average
MA intake from the 40mg/l solution, individuals with high
and low intake were selected for breeding, with this procedure
repeated across four generations of mice. Selection results for two
replicate sets of lines, generated 2 years apart, have been described
(Wheeler et al., 2009; Shabani et al., 2011). The MADR mice
used for these studies were second or later litter offspring of fifth
selection generation replicate 2 breeding pairs maintained within
the Veterans Affairs Portland Health Care System (VAPORHCS)
veterinary medical unit. All mice were MA naïve at the beginning
of each study, and independent sets of mice were used in each
experiment. Although significant sex differences have not been
found in our previous studies of MA consumption, sex could
have an impact when MA intake is greater, thus, equal numbers
of male and female mice were used in each study. Mice for
Experiments 1, 2, 3, and 5 were 108–118, 67–115, 63–117, and
74–97 days old, respectively.
DBA/2J and F2 Cross Mice
Male and female F2 cross mice (B6D2F2) were produced in
the VAPORHCS veterinary medical unit. B6 and D2 mice were
purchased from The Jackson Laboratory (Bar Harbor, Maine,
USA) and reciprocal F1 crosses were paired to produce B6D2F1
and D2B6F1 offspring, which were then crossed to produce the
F2 population tested in Experiment 2. Mice were 69–96 days old.
For Experiment 4, male and female D2 mice were obtained from
The Jackson Laboratory at 8 weeks of age, andwere housedwithin
the animal facility of Minot State University until testing began at
72 days of age.
Housing and Care
All mice were housed in shoe-box cages (31 × 20 × 15 cm;
l × w × h) that were fitted with wire tops and lined with Bed-
O-CobsTM rodent bedding (The Andersons Inc., Maumee, OH,
USA). Mice had free access to rodent chow (Purina 5001, 4.5%
fat content; Animal Specialties Inc., Hubbard, OR or PicoLab R©
Laboratory Rodent Diet 5LOD, 4.5%fat content; Land O’Lakes
Inc., St. Louis, MO, USA) and tap water. Room temperature was
maintained between 20 and 22◦C, and mice were housed on a
12:12 h light:dark schedule, with room lights turned on at 0600 h.
All animals were acclimated to new housing environments for at
least 2 weeks prior to an experiment. Animal care and use were
approved by the Institutional Animal Care and Use Committees
of the VAPORHCS or University of North Dakota and Minot
State University and were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Drinking Solutions
(+) Methamphetamine hydrochloride (MA) was obtained from
Sigma (St. Louis, MO, USA), and used to make fresh drinking
solutions every 4 days. MA drinking solutions were made by
dissolving the appropriate amount of MA with the appropriate
volume of tap water for the mg/l MA solutions utilized.
EXPERIMENTS
Experiments 1, 2, and 3 were conducted at the VAPORHCS,
whereas Experiments 4 and 5 were conducted at Minot State
University.
Experiment 1. Impact of Increasing MA
Concentrations on MA Intake in the MADR
Lines
A two-bottle choice procedure was conducted according to
previous studies (Wheeler et al., 2009; Shabani et al., 2011),
with the exception that MA concentration was increased beyond
40mg/l in 20mg/l increments up to 140mg/l. Each concentration
was offered vs. water for a 4-day period for 18 h per day.
Forty-eight animals (12 per MADR line and sex) were weighed
and individually housed on the first study day in plastic shoe-
box cages with stainless steel wire tops (N10SS model; Ancare,
Bellmore, NY, USA). Drinking bottles were 25-ml graduated
cylinders fitted with stoppers and stainless steel sippers that
were inserted between bars of the cagetops. Food was evenly
distributed around the bottles, and one water bottle was provided
at all times. In the first 48-h period of single housing, animals
were acclimated to consuming fluid from the novel drinking
bottles (one water bottle was offered at this time). Fluid
consumption was determined every 24 h during this period, by
measuring fluid levels in the graduated cylinders. Mice were then
weighed and MA-containing bottles were placed on the cagetops
during the 18-h period 3 h before the dark cycle began and 3 h
into the light phase. Fluid levels were determined for both the
18-h period and the 6-h period, when only water was available.
Body weight data were subsequently collected every 2 days. To
avoid position bias, positions of the water and MA bottles were
alternated every 2 days. Fluid consumption values and body
weight data were used to determine mg/kg of MA consumed
each day. Days 2 and 4 for each MA concentration were averaged
to represent drinking for a particular MA concentration; this
allowed the mice to identify the location of MA after a position
switch and is consistent with the measure used during selective
breeding.
Experiment 2. Impact of Multiple-Bottle
Choice on MA Intake in the MADR Lines
Procedures were identical to those for Experiment 1, with the
exception that 48 MAHDR mice (6 per group and sex) and 24
MALDR mice (3 per group and sex) were offered 1–3 bottles
of MA and 1–2 water bottles. Variation in the number of
bottles across cages precluded alternating their positions, but
MA concentration for all groups was increased every 4 days.
Treatment groups are described in Table 1. Fewer MALDR mice
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TABLE 1 | Groups for Experiments 2, 3, and 4.
Group 18-h bottle ratio Number of bottles: Number of bottles:
MA:H2O 18-h period 6-h period (H2O)
1 1: 1 2 1
2 1: 3 4 1
3 2: 2 4 1
4 3: 1 4 1
H2O, tap water; MA, methamphetamine solution.
were included in this study to reduce unnecessary animal usage,
based on little impact of MA concentration on intake and low
variability in Experiment 1. Likewise, fewer mice were tested per
sex, based on the absence of a sex difference in Experiment 1 or in
other MA drinking studies in these mouse lines (Wheeler et al.,
2009; Shabani et al., 2011).
Experiment 3. Impact of Multiple-Bottle
Choice on MA Intake in B6D2F2 Progenitor
Mice of the MADR Lines
This experiment was conducted as a follow-up to Experiment 2
to compare results for the progenitor F2 mice, which consume
an intermediate amount of MA to the MADR lines (Wheeler
et al., 2009; Shabani et al., 2011). Procedures and groups (Table 1)
were identical to those for Experiment 2. Seventy-twomice (9 per
group and sex) were used in this experiment.
Experiment 4. Impact of Withdrawal Period
on MA Intake in D2 Mice
For this study, the D2 progenitor strain of the MADR lines,
which consumes levels of MA approaching, but somewhat lower
than, those of the MAHDR line (Eastwood and Phillips, 2012;
Harkness et al., 2015), was tested to establish procedures prior
to testing MAHDRmice, which were not as readily available. The
3 MA bottles and 1 water bottle group (Table 1) was chosen from
Experiments 2 and 3, as the group with the greatest MA intake.
Procedures for measurement of MA intake were as described
for Experiments 1–3, except that D2 mice were weighed every
4 days (an unintentional change to the procedure; however,
subsequent examination of body weight data collected every 2
days from other experiments indicated comparable data to every
4-day body weights), and the study was extended to address
whether the length of MA withdrawal impacts subsequent
MA consumption. Under 18-h per day access conditions, MA
concentration was increased every four days from 20 to 40 and
then 80mg/l MA, followed by an additional 16 days, when the
80mg/l concentration was offered every 30 h or every other day
(Figure 1). The 30-h withdrawal period allowed for MA to be
offered every other day and also retained the 18-h access period
on the days on which MA was offered; thus, MA was withdrawn
for 24 plus 6 h or 30 total h between MA access periods. Water
was available at all times. Control group animals were offered
the same number of fluid-filled bottles as the MA group, but all
bottles were filled with tap water. Forty-eight mice (12 per group
and sex) were used in this study.
Experiment 5. Impact of Withdrawal Period
on MA Intake in MAHDR Mice
The procedure used to test MAHDR mice was the same as for
Experiment 4 in D2mice, with the exception that this experiment
was extended to include multiple withdrawal durations after
the first 4 days at 80mg/l MA. Thus, one MA-drinking group
continued with every day, 18-h access to 3 bottles of 80mg/l MA
so that the withdrawal period was the usual 6 h, whereas the
other two groups were offered access either every other day as
in Experiment 4 (30-h withdrawal period), or every 4 days (78-
h withdrawal period). The procedure across days is illustrated in
Figure 2. A control group was included that had access to only
water. Fifty animals (6–7 per group and sex) were used.
Data Analysis
Data were analyzed using SPSS software (IBM R© SPSS R© Statistics
software). The dependent variables were 18-h MA intake, and
total 18-h volume intake. Total volume intake provided a
measure of the effect of MA intake and of number of bottles
on overall fluid consumption. Possible independent variables
were MA concentration, line, group, and sex. Repeated measures
ANOVA was used to determine the impact of increases in MA
concentration and, in experiments 4 and 5, to also determine
change in MA drinking pattern accross days. If the assumption
of sphericity was not met, according to Mauchly’s test (p < 0.05),
a conservative correction of the degrees of freedom, known as
the Greenhouse-Geisser estimate, was used to assess signficance
of the F-ratio. Significant 2-way interactions were followed up
with analyses for simple main effects and then by post-hoc mean
comparisons using the Tukey test, as appropriate. The level for
significance (α) for all statistical tests was set at 0.05.
RESULTS
Experiment 1. Impact of Increasing MA
Concentrations on MA Intake in the MADR
Lines
In the initial line × sex × MA concentration repeated measures
ANOVA, no significant effects involving sex were found;
therefore, data were combined for the two sexes and analyzed
for effects of line and MA concentration. Divergence in MA
intake of the MADR lines increased with access to increasing
concentrations of MA. MAHDR mice escalated their MA intake
at each concentration, whereas the MA intake of MALDR mice
was negligible at lower MA concentrations and increased only
slightly at very high MA concentrations (Figure 3A). These
characterizations were supported by the following statistical
outcomes. There was a statistically significant line x MA
concentration interaction [F(2.4, 92.9) = 26.0, p < 0.001], and
simple main effects analysis revealed a significant effect of MA
concentration within both the MAHDR line [F(2.4, 48.0) = 29.4, p
< 0.001] and MALDR line [F(3.4, 72.3) = 6.7, p < 0.001]. Within-
subjects contrasts of means between a lower MA concentration
and a subsequent higher concentration for the MAHDR line
revealed significant (all ps < 0.01) increases in MA intake at 40,
60, and 100mg/l MA concentrations. A similar analysis within
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FIGURE 1 | Design for Experiment 4. The control group had access to 4 water bottles (not shown), whereas the MA group had access to 3 MA bottles and 1 water
bottle.
FIGURE 2 | Design for Experiment 5. The control group had access to 4 water bottles (not shown), whereas the MA group had access to 3 MA bottles and 1 water
bottle.
the MALDR line revealed a significant (p < 0.01) increase in MA
intake only from the 80 to 100mg/l concentration.
Total fluid consumption during the 18-h MA access period
was also examined (Figure 3B). The MADR lines consumed
similar combined amounts of fluid from the two bottles,
although there was a significant main effect of MA concentration
[F(3.7, 151.5) = 7.8, p < 0.001] that did not significantly interact
with line. Follow-up within-subjects contrasts for data collapsed
on line indicated a significant increase in fluid consumption (p <
0.01) only when the MA concentration was increased from 20 to
40mg/l.
Experiment 2. Impact of Multiple-Bottle
Choice on MA Intake in the MADR Lines
Based on the absence of any significant effects of sex on
MA intake, data were collapsed on this factor and analyzed
by repeated measures ANOVA for the effects of line, group
and MA concentration. As expected, MAHDR mice consumed
significantly more MA than MALDR mice and the difference
in amount consumed was dependent on MA concentration
[Figures 4A,B; F(2.3, 92.6) = 9.5, p < 0.001 for the line × MA
concentration interaction]. However, although the magnitude of
the difference between the lines changed across concentrations,
subsequent analysis with data collapsed on group indicated that
MAHDR mice consumed more MA than MALDR mice at every
concentration (all ps < 0.001). In general, an increasing pattern
of intake was seen across concentrations, but there was not
a significant line × group × MA concentration interaction.
However, for the purpose of model development it was important
to determine if the various groups consumed significantly more
MA across concentrations within-line and whether the MA
to water bottle ratio had a significant impact on MA intake.
Therefore, data were examined separately for each line.
Within the MAHDR line (Figure 4A), there was a significant
group × MA concentration interaction [F(6.0, 76.5) = 4.0, p <
0.005]. Overall, Group 4 consumedmore than twice as muchMA
across most of the MA concentrations, compared to any other
group. For the effect of group within each MA concentration,
significant group differences were detected at each concentration
(ps < 0.005), although MA intake significantly increased across
concentrations in all groups (ps < 0.001). To limit multiple
mean comparisons, and because of our interest in developing a
model of high MA intake, we considered group differences and
concentration effects only with respect to Group 4, and indicate
significant results in Figure 4A. Group 4 consumed more MA
than all other groups for MA concentrations up to and including
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FIGURE 3 | Increasing concentration of MA leads to binge-level MA
intake in selectively bred MA high drinking (MAHDR) mice. (A) mean (±
SEM) mg/kg/18 h MA consumed for MA concentrations offered for 4 days
each and for each mouse line; B: mean (± SEM) total fluid consumed during
the same 18-h periods for each MA concentration and mouse line. +p <
0.001 for the difference between MAHDR and MALDR at each concentration;
**p < 0.01 compared to the next lower MA concentration.
100 mg/l and had significantly higher MA intake compared to
Groups 1 and 2 for the 120 and 140mg/l concentrations as well.
Group 4 exhibited significant escalation of MA intake with each
unit increase in MA concentration up to 100mg/l MA, at which
point MA intake plateaued at a mean (± SEM) level of 26.4 ±
2.2mg/kg. Analysis of data for the MALDR line revealed only
a main effect of concentration [F(2.4, 35.5) = 10.1, p < 0.001],
but no significant main or interaction effect involving group
(Figure 4B). Examination of the concentration effect with data
collapsed on group indicated a significant increase in MA intake
only from 80 to 100mg/l, at which point MA intake plateaued at
4.45± 1.00mg/kg (mean± SEM).
Total fluid consumption (Figures 4C,D) was greater in
MAHDR than MALDR mice [F(1.0, 45.0) = 6.6, p < 0.05 for
the main effect of line] and there was a significant line × MA
concentration interaction [F(4.0, 179.0) = 4.5, p < 0.005], but no
significant effects involving sex or group. A significant effect of
MA concentration was found for both lines (ps < 0.01) and total
fluid consumption of MAHDR mice increased significantly for
MA concentration step increases up to 60mg/l, and plateaued
thereafter, whereas total fluid consumption for MALDR mice
increased significantly only for the MA concentration increase to
40mg/l.
Experiment 3. Impact of Multiple-Bottle
Choice on MA Intake in B6D2F2 Progenitor
Mice of the MADR Lines
There were no effects of sex in the initial analysis, so data for
the sexes were combined and analyzed by repeated measures
ANOVA for the effects of group and MA concentration. F2 mice
increased theirMA intake across concentrations (Figure 5A), but
the increase was impacted by group [F(4.7, 94.5) = 6.3, p < 0.001
for theMA concentration× group interaction]. Significant group
differences were detected at all concentrations (ps < 0.05), and
there were significant effects of concentration within each group
(ps < 0.05). Again, we performed follow-up mean comparisons
within and relative to Group 4 only. Group 4 had higher mean
MA intake at all MA concentrations, except 60mg/l, compared to
Groups 1 and 2, the groups that had access to a single MA bottle.
MA intake for Group 4 did not differ from intake for Group 3,
which had access to 2 MA bottles.
Total fluid consumption during the 18-h MA access period
(Figure 5B) was not impacted by sex, but was affected by group
and MA concentration [F(11.6, 213.3) = 2.2, p = 0.01; for the MA
concentration× group interaction]. There was a significant effect
of MA concentration within each group (ps < 0.05), and analysis
of the effect of group for each MA concentration identified a
significant group effect for total fluid intake only during the
periods when 60mg/l and 120mg/l MA were offered (p <
0.005 and p < 0.05, respectively). Follow-up mean comparisons
identified significant group differences only for 60mg/l MA, as
indicated in Figure 5B.
Experiment 4. Impact of Withdrawal Period
on MA Intake in D2 Mice
To attain high levels of MA intake, only the four-bottle choice
group that had access to 3MA bottles and 1 water bottle, was used
in this study. In addition, the highest concentration offered was
80mg/l MA so that both increases and decreases in intake would
be detectable during the increased withdrawal period phase of the
study. MA drinking acquisition data were analyzed by repeated
measures ANOVA for effects of sex and MA concentration.
Similar to the results for MAHDR mice, D2 mice escalated
their MA intake as MA concentration increased (Figure 6A).
Significant main effects of MA concentration [F(1.3, 28.9) = 56.4,
p < 0.001, and sex F(1, 22) = 4.4, p < 0.05] were found, but there
was no significant interaction of these factors. Overall, females
consumed more MA than males (mean ± SEM = 9.91 ± 1.02
and 6.89 ± 1.02mg/kg/18 h for females and males, respectively,
collapsed on concentration). During theMAdrinking acquisition
period, there were significant increases in MA intake from 20 to
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FIGURE 4 | A high MA bottle to water (H2O) bottle ratio (3MA:1H2O) increased MA intake in MAHDR, but not MALDR, mice. (A,B) Mean (±SEM)
mg/kg/18 h MA consumed for each MA concentration, mouse line, and group; (C,D): Mean (±SEM) total fluid consumed during the same 18-h periods for each MA
concentration, mouse line, and group. +p < 0.01 compared to Group 4 at each MA concentration; *p < 0.05, **p < 0.01, ***p < 0.001 compared to the next lower
MA concentration for Group 4 only.
40mg/l MA (p < 0.001) and 40 to 80mg/l MA (p < 0.001). Data
from post-acquisition days 12–28 (Figure 6B) were analyzed
separately to identify changes in MA intake associated with
increased 30-h withdrawal period; day 12 was included as the
final day on which animals had access to MA after the usual 6-
h withdrawal period. D2 mice reduced their MA intake by more
than half within the first 4 days following the 30-h withdrawal
period (Days 14, 16, 18, and 20) and then their MA intake
plateaued. A significant main effect of day [F(2.5, 54.1) = 13.5,
p < 0.001], and a strong trend toward a sex effect [F(1, 20) = 3.9,
p = 0.07] were found, but there was no sex by day interaction.
There were no statistically significant findings for total fluid
consumption (Figures 6C,D).
Experiment 5. Impact of Withdrawal Period
on MA Intake in MAHDR Mice
There were no significant effects of sex in the initial analysis,
so data for the sexes were combined and analyzed by repeated
measures ANOVA for the effects of group andMA concentration.
During the acquisition period, MAHDR mice escalated their
MA intake, as indicated by a significant main effect of MA
concentration [F(1.2, 39.5) = 127.8, p < 0.001]; however, the 4
intermittent access period groups (defined in Figure 2) were well
matched for mean MA intake during this period, when they were
on identical schedules (Figure 7A). Analysis of data for days 12–
28, representing continued 6-h withdrawal or the transition from
6-h to 30-h or 78-h withdrawal, did not identify any significant
group differences inMA intake (Figure 7B), but there was a main
effect of day [F(3.4, 120.2) = 3.7, p < 0.01]. Mean comparisons
indicated significantly lower MA intake on days 20, 24, and 28,
compared to day 12.
Total fluid consumption during the acquisition phase changed
significantly with concentration [F(1.8, 83.8) = 17.9, p < 0.001],
but there were no effects of sex or group in the initial group× sex
× MA concentration repeated measures ANOVA (Figure 7C).
To examine the effect of concentration, data were collapsed
on sex and group, and means for consecutively increasing MA
concentrations were compared. There was a significant increase
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FIGURE 5 | A high MA bottle to H2O bottle ratio (3MA:1H2O) increased
MA intake in B6D2F2 (F2) mice. (A) Mean (±SEM) mg/kg/18 h MA
consumed for each MA concentration and group; (B) Mean (±SEM) total fluid
consumed during the same 18-h period for each MA concentration and group.
*, #, and & indicate p < 0.05 for Group 4 compared to Group 1, 2, or 3,
respectively.
in fluid intake when MA concentration increased from 20 to
40mg/l (p < 0.001), but not from 40 to 80mg/l (Figure 7C).
Total fluid consumption during days 12–28 (Figure 7D) differed
significantly across days [F(3.6, 171.2) = 4.7, p < 0.005] and groups
[F(3, 46) = 7.8, p < 0.001], but there were no significant sex or
any interaction effects found. Analysis of total fluid consumption
for groups 2–4 revealed no differences between the groups and
no drop in fluid intake across days. Mean fluid intake with the 3
MA access groups (Groups 2–4) collapsed revealed higher intake
of 1.5 ± 0.09ml (mean ± SEM) on average [F(1, 48) = 19.2, p <
0.001], compared to the water control (Group 1).
Finally, to address pattern of MA intake at the individual
level, data were examined for the frequency of MAHDR mice
with amounts of peak MA intake from the 80mg/l concentration
arbitrarily set at above 15mg/kg/18 h or below 10mg/kg/18 h
(Figure 8A). Eighty-five percent of the mice had peak intake
greater than 15mg/kg/18 h, and only 5% had peak MA intake
below 10mg/kg/18 h. The Figure 8A inset shows the same data
for D2 mice from Experiment 4 for comparison; 58% of the D2
mice had peak intake greater than 15mg/kg/18 h, and 21% had
peakMA intake below 10mg/kg/18 h, and the range ofMA intake
values is narrower in the D2 strain. The MA drinking patterns
of 4 representative MAHDR mice (2 animals/sex) from Group
2 are represented in Figure 8B to illustrate the variability across
animals. Group 2 is the 6-h withdrawal group that had access
to MA every day, and represents the MA drinking procedure
used during selective breeding for the 20 and 40mg/l MA
concentrations. Patterns are characterized by peaks of binge-
level MA intake, in one animal of amounts sometimes greater
than 40mg/kg/18 h, followed by troughs, at times of orders of
magnitude lower. Regardless of pattern, binge-like levels of intake
can be seen across animals, with higher binge levels of MA intake
associated with greater escalation as access is prolonged.
DISCUSSION
We have developed methods to study binge-level MA use
patterns in a tractable genetic animal model. In this model,
mice voluntarily consume amounts of MA that are similar to
those reported in humans suffering from MA use disorders.
To develop this model, we began with a mouse line that was
selectively bred for higher levels of MA intake in a relatively
short duration procedure that produced mean MA intake of
∼6mg/kg. By increasing the number of days of MA access along
with progressively increasing MA concentration and increasing
the ratio of MA to water drinking bottles to which the mice
had access, remarkably high levels of MA intake were achieved.
In a two-bottle choice procedure, MAHDR mice consumed
almost 3 times more MA when the MA concentration was
increased in a step-wise fashion to 120mg/l, compared to their
intake at 40mg/l. Adding 2 more MA bottles to this procedure
enhanced MA intake at every MA concentration in MAHDR
mice. Although, MALDR mice exhibited a significant increase
in MA intake (at only a single MA concentration), intake did
not approach binge-like levels and was not dependent upon the
number of MA bottles or the ratio of MA to water bottles. These
procedural alterations also increased MA intake in the B6D2F2
progenitors of the MADR lines and in the higher MA-consuming
D2 inbred strain. However, when a longer period of intermittent
withdrawal was introduced to explore the potential impact of
this manipulation on MA intake, the D2, but not MAHDR,
mice precipitously reduced their MA intake. Hallmarks of drug
disorders are escalation of use and maintenance of excessive
use. Under certain test conditions, our existing MAHDR line
models binge-level MA intake, and when contrasted with
the MALDR line, provides a tool for identifying genetic and
neuropharmacological mechanisms involved in susceptibility to
and development of levels of MA use associated with MA use
disorder.
The difference in MA intake between the MADR lines at
all MA concentrations indicates that genetic factors responsible
for divergence in MA intake during selection also contribute
to the intake of higher MA concentrations. MA intake for
the 20 and 40mg/l MA concentrations in the current studies
was virtually identical to that reported during the selective
breeding of three independent replicate sets of MADR lines
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FIGURE 6 | MA intake is reduced in D2 mice when the intermittent MA withdrawal period is lengthened from 6 to 30h. (A) Mean (±SEM) mg/kg/18 h MA
consumed during the MA drinking acquisition period; (B) Mean (±SEM) mg/kg/18 h MA consumed when access to 80mg/l MA was separated by 30-h withdrawal
(abstinence) periods; (C,D) Corresponding mean (±SEM) total fluid consumption for the MA and water only control groups. ***p < 0.001, compared to the next lower
MA concentration; ###p < 0.001 for the main effect of Day.
(Wheeler et al., 2009; Shabani et al., 2011; Harkness et al., 2015).
Divergence in MA intake between the MADR lines increased as
MA concentration increased, due to escalation of intake in the
MAHDR line. However, it appears that a gradual increase in MA
concentration may be important in this escalation of MA intake;
MA intake of MAHDR mice in Experiment 5 for the 80mg/l
concentration was lower by ∼5 mg/kg/18 h than in Experiment
2, possibly because theMA concentration was more precipitously
increased in Experiment 5 (from 40 to 80mg/l, skipping the
60mg/l MA concentration). Whether such an abrupt change
in MA concentration had aversive effects that reduced intake
is not known. However, it is the case that MAHDR mice
are particularly insensitive to the aversive effects of bolus MA
treatments (Wheeler et al., 2009; Shabani et al., 2011, 2012b).
This is the first study to show that patterns of binge-level
voluntary MA intake can be achieved using a simple multiple-
bottle choice procedure in which the ratio of MA to water
bottles is increased. Increasing access to MAwith additional MA-
containing bottles was based on the results of a 6-bottle choice
ethanol study in which 2–5 ethanol bottles were available, in
addition to one or more water bottles (Tordoff and Bachmanov,
2003). In that study, a substantial enhancement of ethanol intake
was dependent upon the number of ethanol bottles. However,
in the current MA studies, in mice that voluntarily consume
MA, increasing the number of MA bottles was not enough
to appreciably increase MA intake; rather the ratio of MA to
water bottles was the important factor. Thus, animals that had
a 1:1 ratio (i.e.; 1 MA:1 water or 2 MA:2 water) consumed
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FIGURE 7 | MA intake remains high in MAHDR mice under multiple intermittent MA withdrawal periods. (A) Mean (±SEM) mg/kg/18 h MA consumed for
each MA concentration and group, during the MA drinking acquisition period; (B) Mean (±SEM) mg/kg/18 h MA consumed when access to 80mg/l MA was
separated by 6-, 30-, or 78-h withdrawal (abstinence) periods; (C, D) Corresponding mean (±SEM) total fluid consumed. Note: Group 1, 6 h () is water control
group. The MA drinking group 2–4 designations are based on the variable withdrawal length after day 12. See Figure 1 for group information. ***p < 0.001,
compared to the next lower MA concentration; +++p < 0.001, Group 2–4 compared to Group 1.
similar amounts of MA, whereas a higher MA:water bottle
ratio was associated with enhancement of MA intake, and a
lower ratio with suppression of MA intake. That the MA to
water bottle ratio did not significantly impact MA intake in the
MALDR line highlights their general resistance to MA intake
and indicates that genetic proclivity plays a role in the efficacy
of this manipulation. Although the multiple bottle procedure
had an impact on mean MA intake in the F2 mice, greater
variability is clear in Figure 5A for this group of mice, which is
comprised of individuals with different degrees of genetic risk
for MA intake. In a two-bottle 4-h choice procedure in which
MA drinking microstructure was investigated using a system
that detects drinking spout contacts (lickometers), MAHDR
mice had a greater number of MA drinking bouts, longer
MA drinking bouts, shorter interbout intervals and shorter
latency to the first MA drinking bout, compared to MALDR
mice (Eastwood et al., 2014). Operant ethanol studies have
linked shorter interbout interval and greater bout frequency
with craving-like behavior (Samson et al., 1988), which we have
yet to study in the MADR lines. In addition, we have yet to
characterize blood MA level in our increasing MA concentration
ormultipleMA bottle procedures. In themicrostructural analysis
of MA intake, blood MA level at the end of a 4-h session
corresponded with MA intake (Eastwood et al., 2014). Because
mice are nocturnal and consume most of their food and fluid
during the dark phase of the light:dark cycle, it is expected
that most of their MA intake in the 18-h access procedure
used in the current studies occurred during the dark phase.
To determine the ideal time(s) to obtain blood samples that
best reflect intake, we plan to use a lickometer system and
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FIGURE 8 | MAHDR mice are variable in their peak MA intake and MA
intake patterns across time. (A) Frequency of animals in bins of
5mg/kg/18 h, with peak 80mg/l MA intake level ≥ the value along the x-axis.
The inset shows the distribution for D2 mice from Experiment 4 for
comparison; (B) MA drinking patterns of 4 MAHDR mice from Group 2 of
Experiment 5 illustrating variability in patterns of peaks and troughs in
binge-level MA intake. Patterns for Group 2 animals are shown, because they
were given daily MA access, whereas the other groups were given MA access
every other day or every 3 days.
obtain samples at multiple times in independent groups to avoid
disrupting drinking behavior. By using independent groups,
brain samples can also be obtained for determination of brain
MA levels.
The progressive increase in MA intake by MAHDR mice to
eventual sustained excessive intake has strong face validity for
human binge-level use. Approximately 90% of MAHDR mice
tested in our multiple bottle choice procedure consumed binge-
like levels of MA daily. Humans exhibiting high levels of use
take on average 800mg/day, which for a 77 kg person translates
to ∼10mg/kg/day; a majority of these individuals take MA at
intervals of 2–4 h throughout the day (Rawson et al., 2000; Simon
et al., 2002). This pattern of intake is remarkably different from
that for cocaine, which is characterized by a more discontinuous
or intermittent pattern, often with higher doses taken in the
evening and on fewer days per month (Simon et al., 2002;
Rawson et al., 2000). Approximately 40% of MA users in one
study engaged in binge-taking cycles characterized by multiple
episodes of daily use until use was terminated due to lack of
sleep or lack of access to MA (Cheng et al., 2010). According
to estimates, heavy users can take as much as 2–4 grams of MA
in a binge cycle that lasts 1–3 days (Cho and Melega, 2002).
Human deaths associated with toxic MA blood levels have been
reported to be particularly prevalent among individuals that
use MA via the oral route (Inoue et al., 2006). Accumulation
of toxic levels of MA in the blood when orally administered
is more likely because of the relatively slow absorption in the
digestive tract and also slower onset of pharmacological effects
(Schep et al., 2010), coupled to the generally slow clearance of
MA from the blood in humans (Cruickshank and Dyer, 2009).
According to Inoue et al. (2006), MA poisoned patients were very
often diagnosed with edema in multiple organs. In our multiple
bottle choice procedure, some MAHDR mice had extreme peaks
of MA intake of up to 40mg/kg/18 h. Importantly, patterns of
MA intake in MAHDR mice were indicative of binge/crash-
like intake, in which peaks lasted for 2–5 days followed by
troughs of considerably lower amounts. However, there were
no animal deaths and there was no significant difference in
body weight between any of the groups including control mice
(those drinking water only). Rodents metabolize MA more
rapidly than do humans (Riviére et al., 2000; Cho et al., 2001),
so amounts may not accumulate to as high a level. However,
chronic kidney disease and hypertension are frequently found
(>90%) among MA users (Jones and Rayner, 2015), and it
will be important to assess blood and brain MA levels, MA
clearance, and physical and physiological consequences of MA
intake at the levels achieved in our animal model. Whether
tolerance in neurochemical pathways that motivate MA intake
plays a role in increasing MA consumption is not currently
known.
The level of MA intake achieved using our drinking procedure
is comparable to or greater than that obtained in rats using
longer-access operant IV self-administration procedures (Jang
et al., 2013). Rats with 6-h access toMA via the IV route, escalated
and maintained high MA intake levels, whereas rats with 1-h
access did not. Similarly, rats with longer access than 6 h in
an operant IV procedure escalated and sustained high levels of
MA self-administration (Cornett and Goeders, 2013). Rats were
placed in operant boxes for 96 h/session for a total of 5 sessions
separated each time by 72 h. While in the operant boxes, the
animals were restricted to certain amounts of food intake and
allowed to voluntarily self-administer 0.06mg/kg infusions of
MA under a fixed-ratio 1 schedule of reinforcement. Restriction
of food intake may have enhanced drug intake in this study
(Carroll et al., 1979; Carroll and Stotz, 1983). The rats self-
administered ∼75mg/kg/96 h in week five, or a dose of about
0.8mg/kg/h, which is similar to the 1.25mg/kg/h obtained in
the Jang et al. (2013) study. This MA intake level in the 96-h
access study translates to∼14mg/kg/18 h, which is relatively high
MA intake, though somewhat lower than found in our 4-bottle
choice genetic model. The authors stated that there was no MA
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intake escalation or change in binge/crash-like behaviors when
the procedure was continued for longer than 5 weeks (Cornett
and Goeders, 2013).
Our results indicate that there are individual differences
in MA consumption pattern within our genetically selected
MAHDR mouse line. Such differences could arise from genetic,
environmental or both influences. MA consumption patterns in
humans with MA use disorders are also highly variable, such
that some individuals report frequent binge/crash cycles of use
and consume a gram or more in a binge, whereas others report
continuous MA use at lower levels of around 0.3 grams per day
(Simon et al., 2002). In the current study, the initial MA intake of
individual MAHDR mice at lower MA concentrations was more
homogeneous, but MA intake diverged by orders of magnitude
over time at a higher MA concentration (e.g., Figure 8B). Also,
while MAHDR and D2 mice consumed similar amounts of MA
when the intermittent abstinence period was 6 h in a 2- or 4-bottle
choice procedure, only the MAHDR mice sustained their high
levels of MA intake, when the intermittent abstinence period was
lengthened to 30 h. Acute withdrawal effects within a couple of
days of drug abstinence are thought to contribute to compulsive
drug use (Koob and Le Moal, 2005; Jang et al., 2013; Whitfield
et al., 2015). The peak of vulnerability to relapse of MA use in
humans is after 24 h and drops linearly, but stays high for up
to 10 days (McGregor et al., 2005; Zorick et al., 2010). However,
MA metabolism is slower in humans than rodents, which could
impact the duration of vulnerability. Humans that report binge
use of MA have a higher frequency of MA use and higher MA
intake (Cheng et al., 2010), though data appear to be lacking that
indicate how stable MA use is from binge to binge. MAHDR
mice with high binge-level peaks of MA intake when MA was
available at a higher concentration, appeared to escalate their
MA intake, as compared to MAHDR mice with more moderate
peaks of MA intake (Figure 8B). This suggests that binge-level
intake contributes to progressively higher MA intake in this
model.
The difference in MA intake between the MAHDR and D2
mice when a longer period of MA withdrawal was introduced
may be due to differences in sensitivity to acute withdrawal
effects over time. MA withdrawal is characterized by fatigue,
anhedonia, depression, and enhanced craving for MA (Rawson,
2013; Ren et al., 2015). In humans, regardless of the route
of administration, MA has a long plasma half-life of 9–12 h,
whereas subjective effects diminish after 4 h (Cho et al., 2001;
Cruickshank andDyer, 2009). In rodents, MA has amuch shorter
half-life of 70min, whereas locomotor effects last for 3 h or
less (Riviére et al., 1999, 2000; Cho et al., 2001; Shabani et al.,
2012b). DBA/2Ha (Harlan, Dublin, VA) mice exhibited robust
depression-like symptoms, as measured by the tail suspension
test, after a 24-h acute withdrawal from a 7-day regimen of 5
or 10mg/kg/day amphetamine infusion via minipump (Cryan
et al., 2003). To our knowledge, sensitivity to the effects of
acute MA withdrawal is not known in our D2 mice (from
The Jackson Laboratory) or in MAHDR mice, but could differ
and impact MA intake patterns. The level of MA intake of D2
mice was maintained when the intermittent abstinence period
was 6 h, but dropped linearly when the abstinence period was
30 h. Likewise, for operant intragastric ethanol infusion, when
compared to controls, D2 mice had higher ethanol intake within
the first 24 h of acute withdrawal, but when the abstinence
period was longer than 24 h, D2 mice precipitously reduced
their subsequent ethanol intake (Cunningham et al., 2013).
MAHDR mice sustained a high level of MA intake regardless
of withdrawal period. Thus, genetic differences between D2 and
MAHDR mice resulting from selective breeding may contribute
to sustained excessive MA intake. In the current study, total
fluid consumption between the water control and MA groups
did not differ during the MA drinking acquisition period in
either MAHDR or D2 mice, but MA group MAHDR consumed
more total fluid than control group mice during the abstinence
period manipulation phase. It is possible that the MAHDR
mice experienced greater behavioral activation than D2 mice,
corresponding with their greater MA intake, and perhaps greater
thirst. Locomotor activation after 1-h operant oral MA self-
administration sessions has been reported in the MAHDR line
that corresponded with amount of MA consumed (Shabani
et al., 2012a), but has yet to be examined under the current
conditions.
In summary, our genetic mouse model of binge-level MA
intake has some unique advantages. The mice are genetically
vulnerable to excessive MA intake, and escalate and maintain
their intake at binge-like levels similar to those reported in
humans. There are differences among susceptible individual mice
in pattern of intake and escalation, as would be expected among
susceptible humans. The oral intake model is amenable to studies
requiring larger numbers of animals (e.g., pharmacological
studies with multiple drug doses) and for longer duration
studies, because it avoids catheter implantation surgeries and
complications associated with the IV route of self-administration,
although slower absorption via the oral route (Schep et al.,
2010) impacts the rate at which brain responses (e.g., dopamine
increases) may occur. No food restriction, training or sweetener
is necessary with our mouse model, as is often required with
operant IV or oral studies. Animals can voluntarily control their
intake at the microstructural level, which is similar to how
humans control their MA intake, but taste factors need to be
taken into consideration; no differences in the consumption of
bitter, sweet or salty substances have been found in the MADR
lines (Wheeler et al., 2009; Shabani et al., 2011, 2012b). Future
studies will consider individual differences in the emergence
of binge/abstinence cycles that are thought to increase drug-
seeking behaviors associated with drug use disorders (for
review see, Roberts et al., 2013), with a particular focus on
genetic influences and behavioral, neural and physiological
consequences.
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